On July 11, 2025, Bowen Acquisition Corp received a notice from Nasdaq indicating it failed to maintain compliance with listing requirements, including a minimum of 400 total shareholders, leading to a potential delisting. The company intends to appeal this determination and believes it can meet the requirements upon completing its business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.